JP2024503699A5 - - Google Patents

Info

Publication number
JP2024503699A5
JP2024503699A5 JP2023543035A JP2023543035A JP2024503699A5 JP 2024503699 A5 JP2024503699 A5 JP 2024503699A5 JP 2023543035 A JP2023543035 A JP 2023543035A JP 2023543035 A JP2023543035 A JP 2023543035A JP 2024503699 A5 JP2024503699 A5 JP 2024503699A5
Authority
JP
Japan
Prior art keywords
protein
cov
sars
reading frame
open reading
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023543035A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024503699A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/012614 external-priority patent/WO2022155530A1/en
Publication of JP2024503699A publication Critical patent/JP2024503699A/ja
Publication of JP2024503699A5 publication Critical patent/JP2024503699A5/ja
Pending legal-status Critical Current

Links

JP2023543035A 2021-01-15 2022-01-14 バリアント株ベースのコロナウイルスワクチン Pending JP2024503699A (ja)

Applications Claiming Priority (19)

Application Number Priority Date Filing Date Title
US202163138228P 2021-01-15 2021-01-15
US63/138,228 2021-01-15
US202163140920P 2021-01-24 2021-01-24
US63/140,920 2021-01-24
US202163161433P 2021-03-15 2021-03-15
US63/161,433 2021-03-15
US202163173979P 2021-04-12 2021-04-12
US63/173,979 2021-04-12
US202163193547P 2021-05-26 2021-05-26
US63/193,547 2021-05-26
US202163222925P 2021-07-16 2021-07-16
US63/222,925 2021-07-16
US202163241963P 2021-09-08 2021-09-08
US63/241,963 2021-09-08
US202163283905P 2021-11-29 2021-11-29
US63/283,905 2021-11-29
US202163284570P 2021-11-30 2021-11-30
US63/284,570 2021-11-30
PCT/US2022/012614 WO2022155530A1 (en) 2021-01-15 2022-01-14 Variant strain-based coronavirus vaccines

Publications (2)

Publication Number Publication Date
JP2024503699A JP2024503699A (ja) 2024-01-26
JP2024503699A5 true JP2024503699A5 (cg-RX-API-DMAC10.html) 2025-04-14

Family

ID=80168090

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023543035A Pending JP2024503699A (ja) 2021-01-15 2022-01-14 バリアント株ベースのコロナウイルスワクチン

Country Status (6)

Country Link
US (3) US20240139309A1 (cg-RX-API-DMAC10.html)
EP (1) EP4277653A1 (cg-RX-API-DMAC10.html)
JP (1) JP2024503699A (cg-RX-API-DMAC10.html)
AU (1) AU2022207495A1 (cg-RX-API-DMAC10.html)
CA (1) CA3208303A1 (cg-RX-API-DMAC10.html)
WO (1) WO2022155530A1 (cg-RX-API-DMAC10.html)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20220070T1 (hr) 2014-04-23 2022-04-01 Modernatx, Inc. Cjepiva nukleinske kiseline
EP3328394A4 (en) 2015-07-30 2019-03-13 ModernaTX, Inc. CONCATEMEE peptide epitope RNAs
WO2017031232A1 (en) 2015-08-17 2017-02-23 Modernatx, Inc. Methods for preparing particles and related compositions
EP3364949A4 (en) 2015-10-22 2019-07-31 ModernaTX, Inc. CANCER VACCINES
DE20164728T1 (de) 2015-10-22 2021-09-30 Modernatx, Inc. Impfstoffe gegen atemwegsvirus
US12128113B2 (en) 2016-05-18 2024-10-29 Modernatx, Inc. Polynucleotides encoding JAGGED1 for the treatment of Alagille syndrome
SG11201901941YA (en) 2016-09-14 2019-04-29 Modernatx Inc High purity rna compositions and methods for preparation thereof
MA46766A (fr) 2016-11-11 2019-09-18 Modernatx Inc Vaccin antigrippal
WO2018170256A1 (en) 2017-03-15 2018-09-20 Modernatx, Inc. Herpes simplex virus vaccine
WO2018170270A1 (en) 2017-03-15 2018-09-20 Modernatx, Inc. Varicella zoster virus (vzv) vaccine
US11576961B2 (en) 2017-03-15 2023-02-14 Modernatx, Inc. Broad spectrum influenza virus vaccine
MA48047A (fr) 2017-04-05 2020-02-12 Modernatx Inc Réduction ou élimination de réponses immunitaires à des protéines thérapeutiques administrées par voie non intraveineuse, par exemple par voie sous-cutanée
MA49421A (fr) 2017-06-15 2020-04-22 Modernatx Inc Formulations d'arn
WO2019036682A1 (en) 2017-08-18 2019-02-21 Modernatx, Inc. RNA VARIANTS POLYMERASE
EP3668977A4 (en) 2017-08-18 2021-04-21 Modernatx, Inc. HPLC ANALYTICAL PROCESSES
MX2020002348A (es) 2017-08-31 2020-10-08 Modernatx Inc Métodos de elaboración de nanopartículas lipídicas.
US11911453B2 (en) 2018-01-29 2024-02-27 Modernatx, Inc. RSV RNA vaccines
US12151029B2 (en) 2018-09-19 2024-11-26 Modernatx, Inc. PEG lipids and uses thereof
CN112996854B (zh) 2018-09-19 2024-08-30 摩登纳特斯有限公司 高纯度peg脂质和其用途
US12090235B2 (en) 2018-09-20 2024-09-17 Modernatx, Inc. Preparation of lipid nanoparticles and methods of administration thereof
CN113939282A (zh) 2019-01-31 2022-01-14 摩登纳特斯有限公司 制备脂质纳米颗粒的方法
MX2021010075A (es) 2019-02-20 2021-12-10 Modernatx Inc Variantes de arn polimerasa para la formacion de casquetes cotranscripcionales.
MX2021011031A (es) 2019-03-11 2021-12-10 Modernatx Inc Proceso de transcripción in vitro en lotes alimentados.
MA55321A (fr) 2019-03-15 2022-01-19 Modernatx Inc Vaccins à base d'arn contre le vih
US12194089B2 (en) 2020-02-04 2025-01-14 CureVac SE Coronavirus vaccine
MX2023007574A (es) 2020-12-22 2023-09-29 CureVac SE "vacuna de arn contra variantes de sars-cov-2.
WO2022150717A1 (en) 2021-01-11 2022-07-14 Modernatx, Inc. Seasonal rna influenza virus vaccines
US20220363937A1 (en) 2021-05-14 2022-11-17 Armstrong World Industries, Inc. Stabilization of antimicrobial coatings
TWI844087B (zh) * 2021-09-02 2024-06-01 高端疫苗生物製劑股份有限公司 抗新型冠狀病毒(SARS-CoV-2)變異株之免疫組合物及方法
US12397051B2 (en) * 2021-09-14 2025-08-26 Globe Biotech Limited Vaccine for use against coronavirus and variants thereof
WO2023092069A1 (en) * 2021-11-18 2023-05-25 Modernatx, Inc. Sars-cov-2 mrna domain vaccines and methods of use
US12186387B2 (en) 2021-11-29 2025-01-07 BioNTech SE Coronavirus vaccine
US12529047B1 (en) 2021-12-21 2026-01-20 Modernatx, Inc. mRNA quantification methods
US11878055B1 (en) 2022-06-26 2024-01-23 BioNTech SE Coronavirus vaccine
JP2025529906A (ja) * 2022-08-22 2025-09-09 ザ ヘンリー エム ジャクソン ファンデイション フォー ザ アドヴァンスメント オブ ミリタリー メディシン インコーポレイテッド コロナウイルスに対するワクチン
WO2024050483A1 (en) * 2022-08-31 2024-03-07 Modernatx, Inc. Variant strain-based coronavirus vaccines and uses thereof
EP4604996A1 (en) * 2022-10-19 2025-08-27 Immorna (Hangzhou) Biotechnology Co., Ltd. Gene of interest rna formulations
WO2024089638A1 (en) 2022-10-28 2024-05-02 Glaxosmithkline Biologicals Sa Nucleic acid based vaccine
CN117567571A (zh) * 2023-09-28 2024-02-20 上海蓝鹊生物医药有限公司 一种抗新冠病毒的蛋白或mRNA疫苗及其制备方法和应用

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE291925T1 (de) 2001-06-05 2005-04-15 Curevac Gmbh Stabilisierte mrna mit erhöhtem g/c-gehalt und optimierter codon usage für die gentherapie
US9012219B2 (en) 2005-08-23 2015-04-21 The Trustees Of The University Of Pennsylvania RNA preparations comprising purified modified RNA for reprogramming cells
DE102005046490A1 (de) 2005-09-28 2007-03-29 Johannes-Gutenberg-Universität Mainz Modifikationen von RNA, die zu einer erhöhten Transkriptstabilität und Translationseffizienz führen
JP2010531640A (ja) 2007-06-29 2010-09-30 コモンウェルス サイエンティフィック アンド インダストリアル リサーチ オーガニゼイション 毒性化合物の分解方法
DK2205618T3 (en) 2007-09-26 2017-02-20 Intrexon Corp SYNTHETIC 5 'NON-TRANSLATED REGIONS, EXPRESSION VECTORS AND PROCEDURES FOR INCREASING TRANSGENIC EXPRESSION
SG10201408164XA (en) 2007-12-11 2015-01-29 Scripps Research Inst Compositions and methods related to mrna translational enhancer elements
KR20220025112A (ko) 2011-06-08 2022-03-03 샤이어 휴먼 지네틱 테라피즈 인크. Mrna 전달을 위한 지질 나노입자 조성물 및 방법
EA201492055A1 (ru) 2012-06-08 2015-11-30 Шир Хьюман Дженетик Терапис, Инк. ИНГАЛЯЦИОННАЯ ДОСТАВКА мРНК В НЕЛЕГОЧНЫЕ КЛЕТКИ-МИШЕНИ
EP2971033B8 (en) 2013-03-15 2019-07-10 ModernaTX, Inc. Manufacturing methods for production of rna transcripts
ES2967701T3 (es) 2013-03-15 2024-05-03 Translate Bio Inc Mejora sinergística de la entrega de ácidos nucleicos mediante formulaciones mezcladas
SG10201801428RA (en) 2013-08-21 2018-03-28 Curevac Ag Method for increasing expression of rna-encoded proteins
WO2015062738A1 (en) 2013-11-01 2015-05-07 Curevac Gmbh Modified rna with decreased immunostimulatory properties
CA2927254C (en) 2013-12-30 2023-10-24 Curevac Ag Artificial nucleic acid molecules
AU2014375402B2 (en) 2013-12-30 2020-10-01 CureVac SE Artificial nucleic acid molecules
US9259829B1 (en) 2014-08-25 2016-02-16 Cougar Holdings, Llc Roofing and nail removal hammer
EP3405579A1 (en) 2016-01-22 2018-11-28 Modernatx, Inc. Messenger ribonucleic acids for the production of intracellular binding polypeptides and methods of use thereof
SG11201901941YA (en) 2016-09-14 2019-04-29 Modernatx Inc High purity rna compositions and methods for preparation thereof
WO2019036682A1 (en) 2017-08-18 2019-02-21 Modernatx, Inc. RNA VARIANTS POLYMERASE
WO2021154763A1 (en) * 2020-01-28 2021-08-05 Modernatx, Inc. Coronavirus rna vaccines
DE202021004130U1 (de) * 2020-02-04 2022-10-26 Curevac Ag Coronavirus-Vakzine
EP4139616A1 (en) * 2020-04-22 2023-03-01 Pfizer Inc. Coronavirus vaccine
AU2021269042A1 (en) * 2020-05-07 2023-02-02 Translate Bio, Inc. Optimized nucleotide sequences encoding SARS-CoV-2 antigens

Similar Documents

Publication Publication Date Title
JP2023513073A5 (cg-RX-API-DMAC10.html)
JP2024503698A5 (cg-RX-API-DMAC10.html)
AU2019277361B2 (en) Messenger RNA vaccines and uses thereof
JP7789819B2 (ja) 核酸のデリバリーのための新規脂質および脂質ナノ粒子製剤
AU2021201357B2 (en) Stereochemically enriched compositions for delivery of nucleic acids
JP7150608B6 (ja) 多量体コード核酸及びその使用
JP2024099679A (ja) 層間エステル、チオエステル、ジスルフィドおよび無水部分を含む2,5-ジオキソピペラジン脂質
JP2025111544A (ja) 核酸の送達のための新規脂質および脂質ナノ粒子製剤
JP2024099745A5 (cg-RX-API-DMAC10.html)
CA2760776C (en) Lipid compositions for the delivery of therapeutic agents
JP2025019119A (ja) ケイ素を含有するカチオン性脂質
JP2021523916A (ja) メッセンジャーrnaの皮下送達
JP2023535365A (ja) 脂質ナノ粒子に使用するためのカチオン性脂質
JP6752151B2 (ja) 遺伝子サイレンシングにおいて低下したoff−target効果を有するunaオリゴマー
JP2024542188A5 (cg-RX-API-DMAC10.html)
JP2025038101A (ja) 核酸、薬物組成物及び複合体ならびに調製方法と使用
EA024762B1 (ru) Композиции и способы ингибирования экспрессии генов вируса гепатита в
AU2010208035A1 (en) Improved lipid formulation for the delivery of nucleic acids
EA034103B1 (ru) СПОСОБ ЛЕЧЕНИЯ ФЕНИЛКЕТОНУРИИ С ПРИМЕНЕНИЕМ мРНК
JP2018536689A5 (cg-RX-API-DMAC10.html)
JP2022548399A5 (cg-RX-API-DMAC10.html)
JP2011506274A5 (cg-RX-API-DMAC10.html)
JP2022516356A (ja) 原発性線毛機能不全症の治療のための組成物および方法
WO2024012272A1 (zh) 脂质化合物及其应用
WO2025128696A1 (en) Cationic lipid compounds for use in lipid nanoparticles